Tela Bio Earnings Call: Growth Momentum, Cautious Outlook

Tela Bio, Inc. ((TELA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Tela Bio’s latest earnings call painted a picture of solid underlying business momentum tempered by a more cautious near‑term outlook. Management highlighted double‑digit revenue and unit growth, expanding margins, and strengthening traction in Europe and new products, while openly acknowledging execution growing pains from a rapidly rebuilt sales force, contracting delays, and a downshift in 2026 guidance.

Robust Revenue Growth Caps Record Quarter

Full‑year 2025 revenue rose 16% to $80.3 million, while fourth‑quarter sales climbed 18% year over year to $20.9 million, marking a record Q4 for the company. Management emphasized that this growth came despite internal restructuring and market headwinds, reinforcing demand for Tela Bio’s hernia and plastic reconstruction portfolio.

Broad-Based Unit Gains Across Core Portfolio

OviTex unit volumes jumped 22% for the year and 20% in the fourth quarter, underscoring strong procedural adoption among surgeons. PRS units also increased 12% for both the year and Q4, signaling healthy momentum in plastic and reconstructive surgery applications alongside the core hernia franchise.

LiquiFix Shows Early High-Growth Potential

LiquiFix, the company’s newer fixation solution, delivered revenue growth of more than 200% year over year, effectively more than tripling sales. Management positioned LiquiFix as an important adjunct to OviTex, with early adopters broadening usage as they gain confidence in the product’s performance.

European Business Becomes a Meaningful Growth Engine

European revenue reached $12.1 million in 2025, up 17% from $10.3 million a year earlier and now accounting for 15% of total company sales. The call highlighted rapid uptake particularly in the U.K. and The Netherlands, illustrating the potential for international markets to drive incremental growth.

Margin Expansion Supports Gradual Operating Improvement

Gross margin improved to 66% in Q4 and 68% for the full year, compared with 64% and 67% in the prior period, helped by fewer excess and obsolete inventory charges as a share of revenue. Loss from operations narrowed modestly, with Q4 operating loss at $6.6 million versus $8.4 million last year and full‑year operating loss improving slightly to $33.8 million.

Rebuilt Commercial Engine Adds Capacity and Complexity

Tela Bio executed a major commercial overhaul while still growing the top line, ending the year with about 88 U.S. quota‑carrying territory managers versus a prior target of 76 and roughly 90 total sales personnel. Around 40% of the field team was hired in the last six months, while roughly 35% of more tenured reps are already generating over $1 million in annual sales per person.

New Products, Trials, and Leadership Bolster Clinical Profile

The company launched OviTex LTR, a long‑term resorbable option designed to expand its hernia repair toolkit, and began enrolling patients in the ECHO trial focused on hiatal hernia. Tela Bio also elevated Dr. Howard Lang to chief medical officer, signaling a stronger push on clinical education, evidence generation, and surgeon engagement.

Balance Sheet and Board Positioned for Strategy Execution

Tela Bio closed 2025 with $50.8 million in cash and cash equivalents after upsizing and refinancing its debt facility and raising additional equity. Management also pointed to new board talent as a support for long‑term strategic planning and governance as the company scales its commercial operations.

Tempered 2026 Guidance and Softer Q1 Outlook

The company cut its 2026 revenue outlook to at least 8% year‑over‑year growth, a notable step down from previous commentary suggesting roughly 15% growth, and guided Q1 2026 revenue to around $18.5 million. Management framed the year as back‑half weighted with a softer start as newly hired reps ramp, Q1 seasonality plays out, and the business digests recent commercial changes.

New Sales Hires to Drive Growth After Ramp Period

Roughly 40% of U.S. territory managers joined in the last six months, and Tela Bio expects these hires to reach breakeven productivity in roughly six to nine months. Until that ramp is completed, the company anticipates some drag on overall productivity, adding volatility to quarterly revenue trends even as long‑term capacity expands.

Shifting Procedure Mix Weighs on Pricing

Management noted that revenue growth is being partially offset by a shift toward smaller inguinal hernia repair units and lower‑revenue procedures such as inguinal and LPR cases. While ventral hernia now represents about half of procedures, down from roughly 70%, inguinal has risen to about 25%, pressuring average selling prices despite healthy unit growth.

Contracting and Implementation Pose Execution Risks

Converting signed agreements into realized revenue remains a challenge as hospital‑level contracting, group purchasing organization dynamics, and implementation timing extend the sales cycle. The team stressed that these complexities can delay the translation of pipeline wins into recognized sales, adding another source of short‑term variability.

Persistent Losses Underscore Path to Profitability

Tela Bio’s net loss widened modestly to $38.8 million for 2025 compared with $37.8 million in the prior year, while operating losses remained significant despite slight improvement. The company emphasized ongoing investments in sales, marketing, and clinical infrastructure as necessary to support future scale and eventual margin leverage.

Seasonality and Weather Add to Q1 Volume Pressure

Elective procedure volumes were hit by typical January and February seasonality and further disrupted by a major blizzard that postponed surgeries in key markets. While management did not quantify the exact drag, these external factors contributed to the muted expectations for first‑quarter revenue.

Compensation Changes May Temporarily Distort Territory Performance

Sales and marketing commissions increased alongside revenue, with full‑year spend at $63.2 million versus $64.6 million previously as the company optimized its cost structure. A redesigned 2026 compensation plan and territory realignments could cause some temporary geographic soft spots and transitional losses as reps adjust to new incentives and boundaries.

Guidance Signals Cautious Optimism for 2026

For 2026, Tela Bio projected revenue growth of at least 8% from the 2025 base of $80.3 million and guided first‑quarter sales to roughly $18.5 million, while expecting operating and net losses to decline through the year despite a likely step‑up from Q4 to Q1. Management expects a sequential revenue ramp with a noticeable Q1‑to‑Q2 improvement, a smaller seasonal lift into Q3, and a stronger acceleration in Q4 as new sales hires mature and international and newer products contribute more meaningfully.

Tela Bio’s earnings call ultimately balanced evidence of durable demand, a richer product and clinical story, and solid international traction with realistic expectations around ramping a larger sales force and navigating hospital contracting complexity. For investors, the message was one of constructive but measured confidence: the growth engine is being rebuilt for the long term, even if 2026 plays out as a year of consolidation rather than acceleration.